Table 2.
Baseline biochemical and BMD findings
| Patient | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cr (mg/dL) | 1.0 | 1.4 | 0.9 | 0.8 | 0.8 | 0.9 | 0.6 | 0.9 | 0.7 | – |
| Ca (mg/dL) | 9.9 | 10.3 | 10.0 | 9.1 | 9.7 | 9.7 | 10.6 | 9.7 | 10.4 | 9.9 |
| Albumin (g/dL) | 5.0 | 4.5 | – | 4.4 | 1.4 | 4.4 | 3.5 | 4.2 | 4.7 | – |
| PTH (pg/mL) | 23.5 | 28.0 | 50.0 | 53.6 | 18.0 | 6.0 | 20.8 | 30.3 | 33.0 | – |
| 25-hydroxyvitamin D (ng/mL) | 37.0 | 37.5 | 27.0 | 83.5 | 31.4 | 41.0 | 55.0 | 54.0 | 36.3 | 59 |
| BSAP (mcg/L) | 5.4 | 10.7 | 11.1 | 3.9 | 11.4 | 5.2 | 8.1 | 12.9 | 14.1 | – |
| NTX (nmol BCE/mmol Cr) | 11 | 15 | 23 | 19 | 46a | 15 | 22 | 52a | 28 | –a |
| DXA (T-score) | −2.9 | −2.2 | −2.0 | −1.9 | −2.9 | −1.3 | −4.1 | −1.5 | −2.8 | −2.4 |
aThese patients had contralateral complete atypical femoral fracture, which can increase the level of bone turnover markers
Cr creatinine, Ca calcium, PTH parathyroid hormone, BSAP bone-specific alkaline phosphatase, NTX N-telopeptide crosslinks, DXA dual-energy X-ray absorptiometry